CHRU Nancy
Vandœuvre-lès-Nancy, CHRU de Nancy, 54511, France
NCT Number: NCT06526234
Entero-MRI is indicated in Crohn's disease as part of the initial work-up or follow-up (to assess response to treatment, complications). The protocol for carrying out the examination complies with precise specifications set out in international recommendations. To perform the test, the small intestine must be distended with a hyperosmolar product. This protocol is applied to all patients, with no distinction or adaptation.
The total duration of the examination is sometimes difficult for patients to bear. Ingestion of the product to obtain distension of the small intestine is often poorly tolerated by patients.
In a number of cases, the entero-MRI may have been normal due to symptomatology regression or other diagnosis. The patient therefore underwent a complete examination similar to that of a patient with a pathology requiring characterization.
In this context, the investigators hypothesize that fast MR sequences are sufficient to discriminate between normal and abnormal examinations.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Vandœuvre-lès-Nancy, CHRU de Nancy, 54511, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patient with MR enterography examination for follow-up or suspected Crohn's disease
No Exclusion Criteria.
MR enterography
Time frame: Baseline (day 0)
Central Hospital, Nancy, France
Other
Acronym: Fast-MR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT04245215
Crohn Disease, Digestive System Diseases
Zaventem, Belgium
View Trial Details